EUVIMEDEUVIMED entdecken
Crossref

Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway

Hadeer G Gowied, Nesrine S El-Mezayen, Elham A Afify

Life Sciences · 2026-06 · 394 · 124369

DOI: 10.1016/j.lfs.2026.124369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2026-06. Verfasst von Hadeer G Gowied und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt; Pharmacology department, clinic…. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 4, Group A, Member 2, Valsartan, Neuroprotective Agents, Epigenesis, Genetic. Die Arbeit nennt 84 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by degeneration of dopaminergic neurons and associated motor impairments. Current pharmacotherapies only offer symptomatic relief hampered by multiple adverse effects. Herein, pharmacologic, molecular and histopathologic studies were employed to determine whether valsartan (VAL) has functional neurorestorative potential in PD male rat model induced by intraperitoneal (IP) injection of haloperidol (HALO) (1.5 mg/kg/day, for 42 days). Administration of VAL (40 mg/kg PO) for 21 days markedly improved motor functions as revealed by i) reduced muscle rigidity in catalepsy bar test, ii) increase in performance in rotarod and beam walking tests, iii) increased total distance travelled, grooming duration, rearing duration, and maximum speed in open field test. Western blot analysis revealed that VAL restored the markers of dopaminergic neuronal degeneration as indicated by increased protein expression of dopaminergic-specific transcription factors (Nurr1, ASCL1) and mRNA expression of Nurr1 regulatory proteins (PIN1, CoREST), the dopamine (DA) neurons detoxifier ALDH1A1, and markers for dopaminergic transmission (D2 receptor, tyrosine hydroxylase (TH), DA transporter (DAT). Histopathological analyses confirmed neuronal integrity in the substantia nigra (SN). Furthermore, VAL exerted epigenetic modulation by downregulating histone deacetylases HDAC1/5 and upregulating sirtuin 1 (SIRT1), decreased α-synuclein (α-syn) and restored ApoA1. Co-administration of Nurr1 inhibitor meloxicam (MLX; 3 mg/Kg/day PO) significantly attenuated VAL's neuroprotective effects, confirming Nurr1's central role, but did not fully reverse its epigenetic actions. In conclusion, VAL demonstrated potent neuroprotective, restorative of neuronal function, and epigenetic modulatory effects in PD, highlighting its promising role as a novel disease-modifying therapeutic candidate and warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 4, Group A, Member 2ValsartanNeuroprotective AgentsEpigenesis, GeneticBasic Helix-Loop-Helix ProteinsParkinson DiseaseNeuroprotectionAnimalsMaleRatsSignal TransductionRats, Sprague-DawleyDopaminergic NeuronsSubstantia Nigra

Stichwörter der Autor:innen

ASCL1EpigeneticsNurr1Parkinson's diseaseValsartan

Substanzen

Nuclear Receptor Subfamily 4, Group A, Member 2ValsartanNeuroprotective AgentsNr4a2 protein, ratBasic Helix-Loop-Helix Proteins

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt; Pharmacology department, clinical and biological sciences division, College of Pharmacy, Arab Academy…
  • Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University in Alexandria, Alexandria, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt. Electronic address: elham.afifi@alexu.edu.eg.

Zitieren

APA

Gowied, H. G., El-Mezayen, N. S., & Afify, E. A. (2026). Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway. Life Sciences, 394, 124369. https://doi.org/10.1016/j.lfs.2026.124369

Vancouver

Gowied HG, El-Mezayen NS, Afify EA. Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway. Life Sciences. 2026;394:124369. doi:10.1016/j.lfs.2026.124369

BibTeX
@article{Gowied2026,
  author = {Gowied, Hadeer G and El-Mezayen, Nesrine S and Afify, Elham A},
  title = {Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway},
  journal = {Life Sciences},
  year = {2026},
  volume = {394},
  pages = {124369},
  doi = {10.1016/j.lfs.2026.124369}
}
Kostenlos starten →